Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 9, 2026

Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde

View original at globenewswire.com
Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Based on adverse events related to secondary hematologic malignancies, risks could outweigh potential benefits for patients in this treatment regimen

    60% confidence

  • Based on adverse events related to secondary hematologic malignancies, the risks could exceed potential benefits for patients in this treatment regimen

    60% confidence

  • Emerging data from the confirmatory study highlighted a more unfavorable safety profile compared to what was previously observed during clinical evaluation

    60% confidence

  • Emerging data from the confirmatory study highlighted a more unfavorable safety profile compared to what was previously observed during clinical evaluation

    60% confidence

  • The withdrawal should not impact the company's financial guidance

    60% confidence

  • Patient safety remains our priority despite extremely disappointing outcome

    60% confidence

  • Patient safety remains our priority

    60% confidence

  • The withdrawal is not expected to impact the company's financial guidance

    60% confidence

  • Ipsen will work closely with investigators and clinical teams to support patients through next steps and transition plans

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde — Source | Via News | Finance Via News